November 18th, 2026What FAERS Anaphylaxis Data Can and Cannot Tell Biologic Prescribers In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next. Read more
November 18th, 2026Anaphylaxis Reporting Varies Across Respiratory Biologics In FAERS At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics. Read more
November 18th, 2026RENEW: Blinded Interim Data Show FVC Trends With LTI-03 in IPFPooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.Read more
November 17th, 2026Don't Miss a Beat: How Prediction Markets Could Threaten Clinical Trial IntegrityAnkeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.Read more
November 16th, 2026Diabetes Dialogue: OPTIMAL-DIABETES, Survodutide, and Orforglipron at AHA 2026Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.Read more
November 16th, 2026Diabetes Dialogue: Tubeless Mobi Clearance, CGM Choice, and Eversense FreedomDiana Isaacs, PharmD, and Natalie Bellini, DNP, discuss tubeless Mobi's FDA clearance, CVS Caremark's CGM formulary shift, and a transmitter-free implant.Read more
November 16th, 2026FDA Updates Aficamten Label With MAPLE-HCM Data in Obstructive HCMAficamten's label now includes MAPLE-HCM data, in which aficamten monotherapy improved peak VO2 by 2.3 mL/kg/min more than metoprolol at 24 weeks.Read more
November 16th, 2026FDA Approves Dexmedetomidine for At-Home Schizophrenia, Bipolar AgitationDexmedetomidine sublingual film is the first FDA-approved at-home option for acute agitation, based on the phase 3 SERENITY at-home trial.Read more